Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29980423 | 1.00 | MCHR1 (0.43) | MCHR1MAPKAPK2SLC6A9EGLN1PDE10A | |
| SCHEMBL23674081 | 0.92 | MCHR1 (0.40) | MCHR1PDE10APTGDR2LMNATP53 | |
| SCHEMBL23674178 | 0.86 | PTGER2 (0.42) | MCHR1SLC6A9EGLN1PDE10APTGER2 | |
| SCHEMBL23674151 | 0.85 | PSMB5 (0.40) | MCHR1PDE10APTGER2 | |
| SCHEMBL29980220 | 0.85 | PSMB5 (0.40) | MCHR1PDE10APTGER2 | |
| SCHEMBL29903809 | 0.85 | PSMB5 (0.41) | DHODH | |
| SCHEMBL29980354 | 0.84 | FFAR1 (0.40) | MCHR1 | |
| SCHEMBL23674015 | 0.84 | FFAR1 (0.40) | MCHR1 | |
| SCHEMBL23674311 | 0.84 | PDE10A (0.43) | PDE10ALMNADHODH | |
| SCHEMBL29903822 | 0.84 | PDE10A (0.43) | PDE10ALMNADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2021150645-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021150645-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | FABP4, FABP1, FABP3 | MCHR1 4236/4885MAPKAPK2 1122/4885SLC6A9 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.